Accessibility Menu
Creative Medical Technology logo

Creative Medical Technology(NASDAQ) CELZ

Market Cap$5.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 YearN/A
1 Year-67%
1 Month+6%
$1.16
+73.45%
+0.49Today
After hours$1.31+$0.15 (+12.93%)
Creative Medical Technology last closing stock price
MetricPriceDate
Last closeUSD 1.152026-08-06
Creative Medical Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+50.46%USD 0.762026-07-30
1 month+5.5%USD 1.092026-07-07
3 month-50.22%USD 2.312026-05-08
Year to date-41.33%USD 1.962025-12-31
1 year-67.24%USD 3.512025-08-06
3 year-79.39%USD 5.582023-08-07
Since inception-100%USD 150,003.752016-05-19

Creative Medical Technology Financials at a Glance

Market Cap

$5.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.00K

Net Income (TTM)

-$5.76M

EPS (TTM)

-$1.85

P/E Ratio

-0.62

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$1.16

Volume

1,390,801

Open

$1.14

Previous Close

$1.15

Daily Range

$1.01 - $1.75

52-Week Range

$0.62 - $6.25

Estimated Earnings Date

Aug 14, 2026

CELZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Creative Medical Technology

Creative Medical Technology helps people with chronic pain, infertility, and immune disorders. Its therapies use adult stem cells to target specific health problems. Patients may benefit from treatments for back pain or diabetes when other options fail.

Products and Services

  • CaverStem: Stem cell procedure for erectile dysfunction; 100% of 2025 revenue.
  • FemCelz: Stem cell therapy for female sexual dysfunction; no material revenue in 2025.
  • StemSpine: Stem cell treatment for chronic lower back pain; no material revenue in 2025.
  • ImmCelz: Personalized immune cell therapy for stroke and immune disorders; pre-clinical stage.
  • OvaStem: Stem cell therapy for female infertility; no material revenue in 2025.

Growth and Expansion

  • Launched clinical trials for Type 1 Diabetes and chronic back pain in 2024-2025.
  • Partnered with Greenstone Biosciences in 2025 for AI-driven drug discovery.
  • Expanded into biodefense research with AI and stem cell technology in 2025.
  • Received FDA Fast Track designation for a cell therapy in August 2025.
  • Raised capital through warrant exercises and direct offerings in 2024 and 2025.

What Makes Creative Medical Technology Stand Out

The company holds seven patents and 39 pending applications for cell therapies. It integrates artificial intelligence to speed up drug discovery and optimize treatments. Its focus on niche conditions and regulatory milestones sets it apart from larger biotech firms.

Five Things You Need to Know

  • Revenue was $6,000 in 2025, down 46% from 2024.
  • Net loss was $6.0 million in 2025, up 9% from 2024.
  • Research and development spending was $2.3 million in 2025, down 6% year-over-year.
  • Cash and short-term investments totaled $7.2 million at December 31, 2025.
  • All 2025 revenue came from CaverStem kit sales in the U.S.

Bottom Line

Creative Medical Technology remains a pre-commercial biotech focused on cell therapies for hard-to-treat conditions. Its progress depends on clinical trial outcomes and continued funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Timothy Warbington

Website

www.creativemedicaltechnology.com

Headquarters

Phoenix, AZ 85012, US

CELZ Financials

Key Financial Metrics (TTM)

Gross Margin

-1993.17%

Operating Margin

-198049.63%

Net Income Margin

-192066.27%

Return on Equity

-88.50%

Return on Capital

-81.59%

Return on Assets

-89.46%

Earnings Yield

-1.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.74M

Volume

1.39M

Avg. Volume

8.29M

Financials (TTM)

Gross Profit

-$59.80K

Operating Income

-$5.94M

EBITDA

-$5.75M

Operating Cash Flow

-$5.59M

Capital Expenditure

$1.00

Free Cash Flow

-$5.59M

Cash & ST Invst.

$5.85M

Total Debt

$14.19K

Creative Medical Technology Performance Analysis

Creative Medical Technology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 88,6001.0%
20232023-12-31USD 9,000-89.8%
20242024-12-31USD 11,00022.2%
20252025-12-31USD 6,000-45.5%
Creative Medical Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Creative Medical Technology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -9.28N/A
20232023-12-31USD -3.76-59.5%
20242024-12-31USD -3.71-1.2%
20252025-12-31USD -2.52-32.2%
Creative Medical Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3042.2%
Q32025-09-30N/A
Q42025-12-31-52.1%
Q12026-03-3147.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$5.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.36M

N/A

Employees

4

N/A

Net Income

-$1.41M

+14.2%

EBITDA

-$1.43M

+12.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.85M

-24.1%

Total Debt

$14.19K

+0.0%

Accounts Receivable

$105.71K

N/A

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$14.19K

+0.0%

Return on Assets

-89.46%

N/A

Return on Invested Capital

-96.88%

N/A

Free Cash Flow

-$1.32M

+16.9%

Operating Cash Flow

-$1.32M

+16.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALZNAlzamend Neuro Inc
$1.38-3.50%
ADILAdial Pharmaceuticals, Inc.
$4.80+18.52%
APREAprea Therapeutics, Inc.
$0.63+1.85%
ADXNAddex Therapeutics Ltd
$5.80+1.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
SPCXSpace Exploration Technologies
$114.92+0.06%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%

Questions About CELZ

What is the current price of Creative Medical Technology?

Creative Medical Technology is trading at $1.15 per share.

What is the 52-week range for Creative Medical Technology?

Over the past 52 weeks, Creative Medical Technology has traded between $0.62 and $6.25.

How much debt does Creative Medical Technology have?

As of the most recent reporting period, Creative Medical Technology reported total debt of $0.00.

How much cash does Creative Medical Technology have on hand?

Creative Medical Technology reported $5.72M in cash and cash equivalents in its most recent financial results.

What is Creative Medical Technology’s dividend yield?

Creative Medical Technology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services